United States Herceptin Market to Grow with a CAGR of 4.66% through 2030
Growing
awareness of personalized cancer treatment and expanding healthcare access to
monoclonal antibody therapies, is expected to drive the United
States Herceptin Market growth in the forecast period, 2026-2030
According to
TechSci Research report, “United States Herceptin Market – By Region, Competition, Forecast & Opportunities, 2030F”, the United States Herceptin
Market was valued at USD 1.32
Billion in 2024 and is expected to reach USD 1.74 Billion by
2030 with a CAGR of 4.66%. The United States Herceptin market is
evolving within a dynamic oncology landscape, supported by the rise in targeted
therapy preferences and expanded diagnostic capabilities. Growth in molecular
profiling and HER2 testing has led to more precise identification of eligible
patient populations, enabling timely initiation of trastuzumab treatment.
Oncologists are increasingly integrating biologics earlier in treatment cycles,
supported by evidence from real-world studies and clinical trial outcomes that
validate Herceptin's role in improving survival. Patient advocacy efforts and
expanded healthcare coverage have ensured that more individuals are aware of
treatment options and can navigate therapy access more efficiently, fueling
consistent market activity for Herceptin across diverse clinical settings.
Recent
advancements in pharmaceutical development are influencing market behavior,
with a transition toward subcutaneous formulations of trastuzumab gaining
traction due to enhanced patient convenience and reduced chair time. Evolving
treatment guidelines are encouraging shorter-duration regimens and
outpatient-based administration models, which support better resource
utilization in oncology care. Companies are also adopting digital engagement
strategies to educate healthcare providers and streamline patient support
systems, enhancing compliance. Pharmaceutical stakeholders are investing in
real-world evidence collection and outcome tracking to differentiate their
products beyond efficacy, aligning with the ongoing shift toward value-driven
oncology care. These strategies are helping brands remain competitive amid
increasing product parity.
Growth
opportunities within the United States Herceptin market lie in expanding its
therapeutic footprint beyond breast and gastric cancer, where emerging studies
are evaluating its efficacy in rarer HER2-expressing tumors such as colorectal
and lung cancers. Continued investment in companion diagnostics and liquid
biopsy technologies can further optimize Herceptin’s application, improving
patient stratification and minimizing delays in therapy. Collaborations between
biotech firms and academic research centers can accelerate the development of
novel trastuzumab conjugates and combination regimens that address resistance
mechanisms. Biosimilar manufacturers can capitalize on untapped markets in
underinsured populations by offering cost-effective alternatives, particularly
through public health initiatives and Medicaid-driven programs. Leveraging
artificial intelligence and big data analytics in oncology treatment planning
presents another avenue for personalized Herceptin therapy, setting the stage
for sustained innovation and growth.
Browse over XX
market data Figures spread through XX Pages and an in-depth TOC on "United States Herceptin Market”
The United
States Herceptin Market is segmented into product, application, distribution
channel, regional distribution, and company.
Based on the Application,
Stomach/Gastric Cancer emerged as the fastest growing segment in the United
States Herceptin Market during the forecast period. This is due to the increasing incidence of
HER2-positive gastric and gastroesophageal junction (GEJ) cancers, along with
evolving treatment protocols that incorporate trastuzumab as a standard
first-line therapy. Traditionally, Herceptin has been widely used in breast
cancer; however, its proven efficacy in targeting HER2 overexpression in
gastric cancer has driven its clinical adoption in this area. Clinical trials
such as the ToGA (Trastuzumab for Gastric Cancer) study provided pivotal
evidence supporting the use of trastuzumab in combination with chemotherapy,
significantly improving survival outcomes in patients with HER2-positive
metastatic gastric cancer. Regulatory approvals in key markets for this
indication have expanded the scope of Herceptin's therapeutic use, encouraging
oncologists to adopt it more widely for gastric cancer patients.
Based
on the Region, West emerged as the fastest growing region in the United
States Herceptin Market during
the forecast period. This is due to a combination of rising breast cancer
prevalence, enhanced access to oncology care, and progressive healthcare
infrastructure. States like California, Washington, and Colorado have seen
significant improvements in early cancer diagnosis rates and higher adoption of
targeted biologic therapies like Herceptin, particularly in HER2-positive
breast cancer treatment. The presence of leading academic medical centers, such
as Stanford Health and UCLA, and strong participation in clinical trials have
accelerated the usage of monoclonal antibody therapies. Furthermore, favorable
state-level policies that promote biologics and biosimilars, coupled with
increasing insurance coverage under Medicaid expansion, have boosted patient
access to Herceptin-based regimens. Pharmaceutical companies are also
increasingly investing in oncology sales and outreach programs in western urban
centers, which is improving awareness among healthcare professionals and
patients.
Major
companies operating in United States Herceptin Market are:
- Roche
Holding AG
- Pfizer
Inc.
- Samsung
Bioepis Co., Ltd.
- Amgen
Inc.
- Celltrion
Healthcare Co., Ltd.
- Biocon
Limited
- Mylan
N.V. (Viatris)
- Prestige
Biopharma
- Shanghai
Henlius Biotech, Inc.
- Dr.
Reddy’s Laboratories
Download Free Sample Report
Customers can
also request for 10% free customization on this report
“The United States Herceptin Market is
expanding due to the rising investment in HER2-focused clinical research aimed
at exploring new indications and combination therapies involving trastuzumab.
Pharmaceutical companies and academic institutions are actively conducting
trials to assess Herceptin’s efficacy in early-stage cancers, brain metastases,
and in synergy with novel immunotherapies. This growing research pipeline not
only supports label expansion but also strengthens the clinical relevance of
Herceptin across a wider spectrum of oncology applications. The momentum in
R&D is contributing to extended usage, increased prescriptions, and longer
treatment durations, reinforcing Herceptin’s position as a foundational therapy
in HER2-positive cancer care.,” said Mr. Karan Chechi, Research Director of TechSci
Research, a research-based management consulting firm.
“United States Herceptin
Market By Product (Biologic, Biosimilar), By Application (Breast Cancer,
Stomach/Gastric Cancer, Others), By Distribution Channel (Hospital Pharmacy,
Specialty Pharmacy, Others), By Region, Competition, Forecast &
Opportunities, 2020-2030F”, has evaluated the future growth potential of United
States Herceptin Market and provides statistics & information on market
size, structure and future market growth. The report intends to provide
cutting-edge market intelligence and help decision makers take sound investment
decisions. Besides, the report also identifies and analyzes the emerging trends
along with essential drivers, challenges, and opportunities in United States Herceptin
Market.
Contact
TechSci
Research LLC
420
Lexington Avenue, Suite 300,
New York,
United States- 10170
Tel: +1-332-258-6602
Email: [email protected]
Website: www.techsciresearch.com